Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics: Drug–Food and Drug–Viral Interactions01:26

Pharmacokinetics: Drug–Food and Drug–Viral Interactions

A drug interaction occurs when the concurrent use of another drug, food, or an external substance alters the pharmacological activity of a drug. This interaction can modify the action of the original drug, affecting its effectiveness and safety.Drug–food interactions are significant as they impact drug absorption, metabolism, and excretion. For example, grapefruit juice is a well-known disruptor of drug metabolism. It inhibits the cytochrome P450 3A4 enzyme, crucial for the metabolism of many...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Longitudinal Adherence With Stool-Based Testing for Colorectal Cancer Screening in Four United States Health Systems.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026
Same author

Beyond Public Health and Medicine: The Potential Impact of GLP-1s and Other Incretin Mimetic Medications on Greenhouse Gas Emissions.

Journal of public health management and practice : JPHMP·2026
Same author

Provider comments reveal barriers to EHR nudge effectiveness: process evaluation of a null deprescribing trial.

Implementation science communications·2026
Same author

Impacts of a Public Health Emergency on Cancer Testing Rates, Follow-up, and Cancer Diagnosis: an Evaluation of the COVID-19 Pandemic.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Association Between Therapeutic Inertia and Future Hypoglycemia Among Patients with Type 2 Diabetes.

Diabetes epidemiology and management·2026
Same author

Rethinking Mobile Health for Scalable, Personalized Behavioral Care.

JAMA network open·2026

Related Experiment Video

Updated: Jul 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Dietary indiscretion and statin use.

Devin M Mann1, John P Allegrante, Sundar Natarajan

  • 1Division of General Internal Medicine, Mount Sinai School of Medicine, 1470 Madison Avenue, Box 1087, New York, NY 10029, USA. devin.mann@mountsinai.org

Mayo Clinic Proceedings
|August 4, 2007
PubMed
Summary

Statin initiation did not lead to increased saturated fat intake in patients using the medication for primary cardiovascular disease prevention. This study found no significant dietary changes after six months of statin use.

Related Experiment Videos

Last Updated: Jul 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiology
  • Nutritional Science
  • Pharmacology

Background:

  • Cardiovascular disease remains a leading cause of mortality worldwide.
  • Statins are widely prescribed for primary prevention of cardiovascular disease.
  • Concerns exist regarding potential "moral hazard" or dietary indiscretion associated with statin therapy.

Purpose of the Study:

  • To investigate the impact of initiating statin therapy on saturated fat intake.
  • To determine if statin use leads to a decrease in adherence to dietary recommendations.

Main Methods:

  • Longitudinal cohort study involving 71 patients prescribed statins for primary cardiovascular disease prevention.
  • Interviews conducted at baseline, 3 months, and 6 months post-prescription.
  • Data collected on dietary intake (saturated fat), beliefs about diet and medication, and statin adherence.

Main Results:

  • At baseline, a majority of participants expressed a desire to reduce dietary fat and believed statins could manage hyperlipidemia.
  • A significant portion felt statins were prescribed despite their preference for dietary interventions.
  • After 6 months of statin use, no statistically significant change in saturated fat intake was observed.

Conclusions:

  • Initiation of statin therapy for primary cardiovascular disease prevention does not appear to result in increased saturated fat consumption.
  • Patients' dietary intentions and beliefs about statins did not translate into measurable changes in saturated fat intake over 6 months.
  • Findings suggest that statin therapy may not induce the feared "moral hazard" regarding diet.